Company Overview
About Aerska Therapeutics
Aerska Therapeutics is developing a brain-shuttle RNAi (RNA interference) platform for CNS gene silencing — specifically targeting the genetic forms of Alzheimer's disease and Parkinson's disease caused by dominant mutations that can be silenced by RNA therapeutics. The company raised $39 million in February 2026, doubling its prior $21 million Series A round, led by ex-AstraZeneca neuroscience executives who validated both the science and the commercial opportunity.
Business Model & Competitive Advantage
The blood-brain barrier (BBB) is the primary obstacle to CNS gene silencing: RNA therapeutics that work in peripheral tissues cannot efficiently reach the brain because the BBB prevents most molecules from crossing from blood to brain tissue. Aerska's brain-shuttle technology uses receptor-mediated transcytosis — hijacking the brain's natural nutrient transport mechanisms — to deliver RNAi payloads to specific CNS targets without requiring intrathecal injection or viral vectors.
Competitive Landscape 2025–2026
Genetic forms of Alzheimer's (APOE4, PSEN1/2 mutations) and Parkinson's (LRRK2, SNCA mutations) are among the most genetically validated drug targets in neuroscience: the mutations that cause these diseases are known, the proteins they encode are well-characterized, and reducing their expression is the mechanistically justified therapeutic strategy. Aerska's focus on genetic forms provides a biomarker-selected patient population where clinical success probability is meaningfully higher than in unselected Alzheimer's and Parkinson's populations.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Aerska Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Aerska Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Aerska Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Aerska Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aerska Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →